SUNZEN BIOTECH BHD
KLSE (MYR): SUNZEN (0148)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
0.315
Today's Change
0.00 (0.00%)
Day's Change
0.315 - 0.315
Trading Volume
51,200
Details of Changes
Securities After Change
Transactions
| Ann. Date | Name | Details of Changes | Securities After Changes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Date | Type | No. of Shares | Price | Direct (%) | Indirect (%) | Total (%) | ||||
Discussions
5 people like this. Showing 50 of 2,219 comments
caught some at 0.31... cheap & nice to hold... if this week can climb back like you say then nice lor..
2024-08-06 16:01
next qr should see some improvement with the positive growth of biotech industry
2024-08-07 16:20
0.31-0.32 is a steady & cheap entry price now, Sunzen entering the healthcare sector will push the price further up
2024-08-08 15:07
Strong growth every quarter, Sunzen future prospect is really bright with new acquisition
2024-08-09 16:10
Next quarter's revenue and net profit will both increase quarter-on-quarter and year-on-year, I believe
2024-08-12 20:08
Sunzen has decreased current liabilities to 6.3% of total assets over this period. Good sign
2024-08-13 16:15
I just watched it. Must say the new management seems to be doing the right thing compare to the previous one. At least now SUNZEN is no longer losing money but making profit
2 months ago
Hopes the Xmegami lenglui will buy in sunzen also since their earning so high every month
1 month ago
Watched the technical analysis here https://youtu.be/9V0_mkxG1sw?si=M-l0iuIJeU4w9q5Q
1 month ago
Dow Jones
Dow Jones Industrial Average
42,011.59
-184.93
0.43%
Nasdaq
NASDAQ Composite
17,918.47
-6.64
0.03%
1 month ago
Share price still steady after that, biggie0000. We wait for the next rally to come
2 weeks ago
As consumers pay more and more attention to preventive health care and natural remedies, Sunzen's traditional Chinese medicine and human health supplement products have huge growth potential
2 weeks ago
Nice grab, gloveshapiro. If the QR is good as expected, it probably will break 35 cents
2 weeks ago
Sunzen Biotech eyes bigger share of China bird’s nest market. Sunzen subsidiary Ecolite Biotech Manufacturing Sdn Bhd has received approval from China’s customs authority in October last year to export its bottled bird’s nest to the country up to 2028.
1 week ago
The demand for edible bird’s nest products is indeed strong in China, Hong Kong, and other parts of Southeast Asia. The Chinese market, in particular, is one of the largest consumers of bird’s nests, driven by a cultural preference for traditional health products and rising disposable incomes
1 week ago
Sunzen's loan financing business is expected to continue to grow given the increasing trend in the number of applications and approvals, mainly due to our ability to provide fast and efficient services and structure more flexible loan packages to meet the needs of the SME market.
6 days ago
Acquisition of Eye Nation Medical is expected to contribute positively to the future financial performance of the Sunzen group, enhancing the group’s revenue and profitability, as it is secured by a profit guarantee of an audited profit after tax of RM2.60 million over the next two financial years
4 days ago
Then SUNZEN will be able to achieve over RM1 million of net profit in the next quarter 😀
3 days ago
more expansion into the healthcare sector, Sunzen keep building & growing... TP 0.40
2 days ago
Post a Comment
Featured Posts
Introducing MY's First IPO Fund for Sophisticated Investors!
New Update. Discover investment communities that resonate with your ideas
M & A Value Partners IPO Equity Fund has been launched - Targeted 13% Return p.a
Latest Videos
Apps
Top Articles
1
2
4
save malaysia!
Visa-free travel to China extended for Malaysians to 30 days
5
6
7
BFM Podcast
8
#
Stock
Score
Daily Stocks
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Stock Name
Last
Change
Volume
Featured Advertisers / Partners
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
RamsyNa
Looks like today is a great opportunity to accumulate
2024-08-05 20:43